Research Article

Identification of Potential Therapeutic Targets and Molecular Regulatory Mechanisms for Osteoporosis by Bioinformatics Methods

Li Zhang, Yunlong Yang, Dechun Geng, and Yonghua Wu

1Department of Geriatrics, The Municipal Hospital of Suzhou, Jiangsu, China
2Department of orthopedics, The First Affiliated Hospital of Soochow University, Jiangsu, China

Correspondence should be addressed to Yonghua Wu; wuping38891011@163.com

Received 1 October 2020; Revised 6 January 2021; Accepted 8 February 2021; Published 10 March 2021

Academic Editor: Chenshuang Li

Copyright © 2021 Li Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Osteoporosis is characterized by low bone mass, deterioration of bone tissue structure, and susceptibility to fracture. New and more suitable therapeutic targets need to be discovered. Methods. We collected osteoporosis-related datasets (GSE56815, GSE99624, and GSE63446). The methylation markers were obtained by differential analysis. Degree, DMNC, MCC, and MNC plug-ins were used to screen the important methylation markers in PPI network, then enrichment analysis was performed. ROC curve was used to evaluate the diagnostic effect of osteoporosis. In addition, we evaluated the difference in immune cell infiltration between osteoporotic patients and control by ssGSEA. Finally, differential miRNAs in osteoporosis were used to predict the regulators of key methylation markers. Results. A total of 2351 differentially expressed genes and 5246 differentially methylated positions were obtained between osteoporotic patients and controls. We identified 19 methylation markers by PPI network. They were mainly involved in biological functions and signaling pathways such as apoptosis and immune inflammation. HIST1H3G, MAP3K5, NOP2, OXA1L, and ZFPM2 with higher AUC values were considered key methylation markers. There were significant differences in immune cell infiltration between osteoporotic patients and controls, especially dendritic cells and natural killer cells. The correlation between MAP3K5 and immune cells was high, and its differential expression was also validated by other two datasets. In addition, NOP2 was predicted to be regulated by differentially expressed hsa-miR-3130-5p. Conclusion. Our efforts aim to provide new methylation markers as therapeutic targets for osteoporosis to better treat osteoporosis in the future.

1. Introduction

Osteoporosis is defined as a systemic skeletal disease characterized by reduced bone density and deterioration of bone tissue microstructure, resulting in increased bone fragility and sensitivity to fracture [1]. The clinical definition of osteoporosis is that the bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DEXA) is below the average level in young people [2]. In the absence of effective treatment, as many as one in every two Americans over the age of 50 will develop osteoporosis by 2020 [3]. In Italy, approximately 3.5 million women and 1 million men suffer from osteoporosis [4]. The number of fractures worldwide is expected to double in the coming decades and even by 2040 [5]. The high social and personal costs incurred by osteoporosis pose a challenge to public health and physicians, especially because most patients with osteoporosis remain untreated. This has prompted researchers to develop new diagnostic markers and therapeutic targets for osteoporosis in recent years.

Osteoporosis is caused by an imbalance in bone remodeling. To maintain bone homeostasis, the functions of osteoblasts and osteoclasts are coordinated by a variety of molecules [6]. Studies have shown that the spontaneous increase of proinflammatory cytokines such as interleukin (IL)-6, tumor necrosis factor alpha, and osteoclasts enhance the ability of osteoclasts to absorb bone, thus promoting the occurrence of osteoporosis [7, 8]. It has also been observed
clinically that the degree of osteoporosis corresponds to the degree of inflammation [9]. Many factors interact, and each gene also plays an important role [10, 11].

microRNAs (miRNAs) are a superfamily of small molecules (22 nucleotides), single-stranded noncoding RNAs [12]. Due to the advancement of high-throughput sequencing technology, more and more new miRNAs have been found to be associated with osteoporosis [13, 14]. miRNAs participate in osteoporosis research by regulating target genes [15]. On the other hand, some gene methylation is also associated with osteoporosis [16]. Studies speculate that methylation modification of genes in osteoporotic patients may be a compensatory mechanism to combat osteoporosis-related bone loss [17]. So far, large numbers of differentially methylated CGPs associated with BMD have been identified in bone specimens with large bone density differences [18].

However, the pathogenesis of osteoporosis is still complex and has not been fully elucidated. Multimomics data can provide a clearer and more comprehensive understanding of the pathogenesis of osteoporosis. In this study, we attempt to study the molecular mechanism of osteoporosis through sequencing data by using bioinformatics methods. It aims to reveal potential therapeutic targets.

2. Materials and Methods

2.1. Data Sources. The sequencing datasets were collected from the gene expression omnibus (GEO) database. We screened the osteoporosis-related datasets with a sample size greater than 10. GSE56815 included gene expression profiling of circulating monocytes from 40 extremely high and 40 extremely low hip bone mineral density (BMD) subjects. GSE62402 included transcriptome gene expression of peripheral blood monocytes from 5 low BMD to 5 high BMD subjects. GSE13850 included gene expression profiling of B cells was isolated from 10 low BMD to 10 high BMD patients. All the expression data had been preprocessed using RMA (robust multiarray average) normalization. GSE99624 included methylation profiling of whole peripheral blood from 32 primary osteoprotic patients and 16 control individuals. Data were normalized with internal controls according to standard procedures of Illumina. Methylation level at each locus was calculated with the GenomeStudio Methylation module as beta-value (ranging from 0 to 1). GSE63446 included microRNA profiling of 10 samples. miRNA QC Tool software was used for data summarization, normalization, and quality control.

2.2. Analysis of Differentially Expressed Genes and Methylation Position. The differentially expressed genes were obtained from high and low BMD subjects through the limma R software package. The differentially methylation positions were obtained by chAMP software package. The P value < 0.05 as threshold for nominally significant differential expression. Gene expression and methylation were in opposite directions and were considered methylation markers which regulated by methylation.

2.3. Protein-Protein Interaction Network. The protein-protein interaction (PPI) network was constructed by putting methylation markers into the Search Tool for the Retrieval of Interacting Genes (STRING) (https://string-db.org) [19]. Important methylation markers were obtained through Degree, DMNC, MCC, and MNC plug-ins of Cytoscape, respectively.

2.4. Enrichment Analysis. The enrichment analysis of gene ontology (GO) functional analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was performed for important methylation markers by the clusterProfiler R software package [20]. The cellular component (CC), biological process (BP), and molecular function (MF) terms were included in GO analysis. Gene Set Enrichment Analysis (GSEA) of genes in osteoporosis and control was carried out by the clusterProfiler R software package. The P value < 0.05 was considered to indicate a statistically significant difference.

2.5. Infiltration of Immune Cells. The marker gene set for immune cell types was obtained from Bindeia et al. [21]. Single-Sample Gene Set Enrichment Analysis (ssGSEA) program was used to quantify the infiltration levels of immune cell types. The ssGSEA applies gene signatures expressed by immune cell populations to individual samples.

2.6. Recognition of miRNA Regulation. An integrative retrieval from TargetScan, a miRNA-target interaction (MTI) database, was applied to search for experimentally validated target miRNAs of key methylation markers. The predicted miRNAs were intersected with differentially expressed miRNAs to obtain regulatory factors that regulate key methylation markers.

3. Results

3.1. Differentially Expressed Genes and Methylation Position in Osteoporosis. By comparing the differentially expressed genes (DEGs) between osteoporotic patients and controls, we obtained 2351 statistically significant DEGs (Figure 1(a)). These included 1594 upregulated DEGs and 757 downregulated DEGs (Figure 1(b)). The DEGs may be involved in the disease process of osteoporosis. On the other hand, we compared changes in methylation levels in osteoporotic patients. A total of 5246 differentially methylation positions (DMPs) were found in osteoprotic patients compared with controls (Figure 1(c)). Methylation occurs in a larger proportion at the position of chr1 (Figure 1(d)). Genes whose methylation levels were in opposite directions to those of gene expression levels were considered methylation marks. By comparing DEGs and DMPs, we found 247 genes identified as methylation marks with this property (Figure 1(e)).

3.2. Identification of Key Methylation Markers. To further identify key methylation markers, we put 247 genes into the PPI network. Important methylation markers were obtained through Degree, DMNC, MCC, and MNC in Cytoscape, respectively (Figure 2(a), Figure S1). Taking their intersecting genes, we identified 19 methylation markers (Figure 2(b)). Among them, HIST1H3G, MAP3K5, NOP2,
Gene Z-score

Group
Case
Control

Boxplot

Figure 1: Continued.
osteoporosis-related methylation markers were significantly involved in the process of osteoporosis. We identified 19 important methylation markers which were mainly enriched in the MAPK signaling pathway, and neurotrophin signaling pathway. It mainly included the upregulated signal transduction by p53 class mediator, and interleukin-7-mediated signaling pathway, and the downregulated response to vitamin D (Figure 3(a)). Enrichment results of KEGG showed that methylation markers were mainly enriched in autoimmune thyroid disease, and steroid hormone biosynthesis (Figure 3(c)).

3.3. Functional Enrichment of Methylation Markers. Enrichment analysis revealed that 19 methylation markers were significantly involved in biological processes (BP), cell composition (CC), molecular function (MF), and KEGG pathways. It mainly included the upregulated signal transduction by p53 class mediator, and interleukin-7-mediated signaling pathway, and the downregulated response to vitamin D (Figure 3(a)). Enrichment results of KEGG showed that methylation markers were mainly enriched in the MAPK signaling pathway and Neurotrophin signaling pathway (Figure 3(b)). In addition, GSEA results showed that osteoporosis-related methylation markers were significantly enriched in autoimmune thyroid disease, and steroid hormone biosynthesis (Figure 3(c)).

3.4. Difference of Immune Infiltration in Osteoporosis. Compared with the control group, most of the immune cells infiltrated increased in osteoporosis (Figure 4(a)). Among them, iDC, NK CD56dim cells, and DC showed the most significant difference. Differentially infiltrated immune cells were clustered into four categories and positively or negatively correlated with each other (Figure 4(b)). The positive correlation between NK CD56brigh cells and NK cells was the strongest in osteoporosis samples, and that between Cytotoxic cells and T cells was the strongest in control samples (Figure 4(c)). Importantly, among the key methylation markers we identified, MAP3K5 had the strongest correlation with immune cells (Figure 4(d)). The differential expression of MAP3K5 was also validated by GSE13850 and GSE62402. In addition, we obtained differentially expressed miRNAs between osteoporosis and controls, and identified the regulatory relationship between differentially expressed hsa-miR-3130-5p and NOP2 by TargetScan (Figure 4(f)).

4. Discussion
In this study, we identified genes modified by methylation through analyzing gene expression and methylation levels in osteoporosis patients. Through the PPI network, we screened the key methylation markers, which were mainly involved in apoptosis, immune inflammation and other related functions. Differences in immune cell infiltration showed that innate immune response was more associated with osteoporosis.

Methylation markers have been acted as biological markers recently [22, 23]. In this study, we also similarly found methylation markers involved in the process of osteoporosis [24]. We identified 19 important methylation markers which enriched some important biological functions and signaling pathways may be associated with osteoporosis. Stability regulation of p53 plays an important role in osteoblast differentiation [25]. At the same time, downregulation of p53 expression may be a potential marker for drug treatment of osteoporosis [26, 27]. Interleukin-7 (IL-7) is a potent osteoclast [28]. IL-7 increases bone loss mainly by increasing T cells produced by RANKL and TNF [29]. Vitamin D and its active metabolites are important components of the immune and hormonal systems, not only controlling phosphorus and calcium homeostasis but also playing an important role in providing a variety of biological effects [30]. Studies have confirmed the importance of maintaining adequate levels of vitamin D to prevent and treat osteoporosis [31]. Interleukin activates priming signals through mitogen-activated protein kinase (MAPK), leading to the expression of proinflammatory cytokines and chemokines, plays a central role in bone resorption, leading to osteoporosis [32]. Drugs can also play a role in the treatment of osteoporosis.
by inhibiting the activation of the MAPK signaling pathway [33]. Neurotrophin signaling pathway has also been confirmed to be involved in the process of osteoporosis [34].

Among key methylation markers we identified, the MAP3 kinase-5 (MAP3K5), also known as apoptosis signal-regulating kinase 1 (ASK1), is a serine/threonine protein kinase that activates JNK and p38 and induces apoptosis [35]. Importantly, we validated the differential expression of MAP3K5 in three sets of data. Consistent with our findings, NOP2 was identified as a candidate gene associated with bone mineral density (BMD) [36]. OXA1L is differentially expressed in estrogen-exposed osteoblasts and is involved in bone formation [37]. Studies have shown that overexpression of ZFPM 2 inhibits the differentiation of osteoblasts [38]. We obtained better AUC values for key methylation markers, which may have the ability to differentiate osteoporosis.
results once again confirm that methylation modification is associated with the occurrence and development of osteoporosis and that intervening modification of gene methylation may be a potential therapeutic means.

The immune system plays an increasingly important role in bone pathophysiology, which has led to a new research field: bone immunology [39]. From the enrichment results, most methylation markers are involved in the immune inflammatory response. This was also confirmed in the differential results of immune cell infiltration. We found that iDC, NK CD56dim cells, and DC had increased differential infiltration in osteoporosis. Bone remodeling is regulated by
Different immunity cells in GSE56815 with case vs. control

(a) Case infiltration

(b) Control infiltration

Figure 4: Continued.
the interaction of osteoclasts and osteoblasts with complex factors such as immune cells (DCs, etc.) and cytokines [40]. Bone marrow dendritic cells play an important role in the induction of T cell inflammatory cytokine production, which may be related to postmenopausal bone loss [41]. Invariant natural killer T cells (iNKT) cells have long-term effects on bone physiology in osteoporosis patients and play an important role in bone loss in osteoporosis patients [42]. This suggests that immune changes in osteoporotic patients may be the underlying molecular mechanism of pathogenesis, which may also serve as a potential therapeutic target.

Like other studies, this study has some limitations. Firstly, our analytical data are derived from public database with relatively small sample sizes. Second, important analysis results also require experimental validation of clinical samples. In conclusion, we conducted a comprehensive bioinformatics analysis and identified a set of target genes potentially relevant for osteoporosis treatment and biological pathways that may lead to changes in bone density. Our results reveal valuable insights into the pathogenesis of osteoporosis and methylation markers that may have a treatment role. These results will help to provide hypotheses for future functional studies.

Figure 4: The infiltration of immune cells in osteoporosis. (a) The difference of immune cell infiltration between osteoporosis and control. (b) Clustering of immunoinfiltrating cells. (c) The correlation between immune infiltrating cells in osteoporosis or control samples. (d) The correlation between key methylation markers and immune cells. (e) The differential expression of MAP3K5 in GSE56815, GSE13850, and GSE62402. (f) Differentially expressed miRNAs between osteoporosis and controls.
Data Availability

The raw data can be accessed from datasets of GSE56815, GSE99624, and GSE63446.

Conflicts of Interest

All authors claimed no competing conflicts of interest.

Acknowledgments

This work was funded by Suzhou Science and Technology Plan Project (SS2019069).

Supplementary Materials

Figure S1. The important genes were screened through DMNC (a), MCC (b), and MNC (c) plug-ins in Cytoscape. The edge of the node was the methylation level and the nucleus were the expression level. Colors from blue to red indicated that values change from small to large. The size of the node was the degree of the connectivity. (Supplementary Materials)

References

[1] W. A. Peck, “Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis,” The American Journal of Medicine, vol. 94, no. 6, pp. 646–650, 1993.
[2] J. A. Kanis, E. V. McCloskey, H. Johansson, A. Oden, L. J. Melton 3rd, and N. KHALTAEV, “A reference standard for the description of osteoporosis,” Bone, vol. 42, no. 3, pp. 467–475, 2008.
[3] E. M. Lewiecki, D. Leader, R. Weiss, and S. A. Williams, “Challenges in osteoporosis awareness and management: results from a survey of US postmenopausal women,” Journal of Drug Assessment, vol. 8, no. 1, pp. 25–31, 2019.
[4] R. Nuti, M. L. Brandi, G. Checchia et al., “Guidelines for the management of osteoporosis and fragility fractures,” International and Emergency Medicine, vol. 14, no. 1, pp. 85–102, 2019.
[5] A. Oden, E. V. McCloskey, J. A. kanis, N. C. Harvey, and H. Johansson, “Burden of high fracture probability worldwide: secular increases 2010-2040,” Osteoporosis International, vol. 26, no. 9, pp. 2243–2248, 2015.
[6] Y. Ukon, T. Makino, J. Kodama et al., “Molecular-based treatment strategies for osteoporosis: a literature review,” International journal of molecular sciences, vol. 20, no. 10, 2019.
[7] C. Scheidt-Nave, H. Bismar, G. Leidig-Bruckner et al., “Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause,” The Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 5, pp. 2032–2042, 2001.
[8] J. Pföhlischer, R. Koziltz, M. Pfohl, and H. Schatz, “Changes in proinflammatory cytokine activity after menopause,” Endocrine Reviews, vol. 23, no. 1, pp. 90–119, 2002.
[9] N. M. Al-Daghri, I. Aziz, S. Yakout et al., “Inflammation as a contributing factor among postmenopausal Saudi women with osteoporosis,” Medicine, vol. 96, no. 4, article e5780, 2017.
[10] Y. Liu, Y. Wang, N. Yang, S. Wu, Y. Lv, and L. Xu, “In silico analysis of the molecular mechanism of postmenopausal osteoporosis,” Molecular Medicine Reports, vol. 12, no. 5, pp. 6584–6590, 2015.
[11] K. Azuma, Q. Zhou, and K. Y. Kubo, “Morphological and molecular characterization of the senile osteoporosis in senescence-accelerated mouse prone 6 (SAMP6),” Medical Molecular Morphology, vol. 51, no. 3, pp. 139–146, 2018.
[12] N. Bushati and S. M. Cohen, “microRNA functions,” Annual Review of Cell and Developmental Biology, vol. 23, no. 1, pp. 175–205, 2007.
[13] H. Ding, J. Meng, W. Zhang et al., “Medical examination powers miR-194-5p as a biomarker for postmenopausal osteoporosis,” Scientific Reports, vol. 7, no. 1, p. 16726, 2017.
[14] T. Yu, X. You, H. Zhou et al., “MiR-16-5p regulates postmenopausal osteoporosis by directly targeting VEGFA,” Aging (Albany NY), vol. 12, no. 10, pp. 9500–9514, 2020.
[15] H. Zhang, W. Ding, F. Ji, and D. Wu, “MicroRNA-410 participates in the pathological process of postmenopausal osteoporosis by downregulating bone morphogenetic protein-2,” Experimental and Therapeutic Medicine, vol. 18, no. 5, pp. 3659–3666, 2019.
[16] Y. Zhou, L. Yang, H. Wang et al., “Alterations in DNA methylation profiles in cancellous bone of postmenopausal women with osteoporosis,” FEBS Open Bio, vol. 10, no. 8, pp. 1516–1531, 2020.
[17] Y. Cao, B. Wang, D. Wang et al., “Expression of sclerostin in osteoporotic fracture patients is associated with DNA methylation in the CpG island of the SOST gene,” International Journal of Genomics, vol. 2019, Article ID 7076513, 8 pages, 2019.
[18] S. Reppe, T. G. Lien, Y. H. Hsu et al., “Distinct DNA methylation profiles in bone and blood of osteoporotic and healthy postmenopausal women,” Epigenetics, vol. 12, no. 8, pp. 674–687, 2017.
[19] X. Shi, T. Huang, J. Wang et al., “Next-generation sequencing identifies novel genes with rare variants in total anomalous pulmonary venous connection,” eBioMedicine, vol. 38, pp. 217–227, 2018.
[20] C. Gu, X. Shi, Z. Huang et al., “A comprehensive study of construction and analysis of competitive endogenous RNA networks in lung adenocarcinoma,” Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, vol. 1868, no. 8, p. 140444, 2020.
[21] G. Bindea, B. Mlecnik, M. Tosolini et al., “Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer,” Immunity, vol. 39, no. 4, pp. 782–795, 2013.
[22] C. Gu, X. Shi, C. Dai et al., “RNA m6A modification in cancers: molecular mechanisms and potential clinical applications,” The Innovation, vol. 1, no. 3, p. 100066, 2020.
[23] C. Gu and C. Chen, “Methylation in lung cancer: a brief review,” Methods in Molecular Biology, vol. 2204, pp. 91–97, 2020.
[24] C. Qu, F. Yu, K. Su et al., “Multi-omics data integration for identifying osteoporosis biomarkers and their biological interaction and causal mechanisms,” iScience, vol. 23, no. 2, article 100847, 2020.
[25] Y. R. Yang, C. W. Li, J. H. Wang et al., “Ubiquitylomes analysis of the whole blood in postmenopausal osteoporosis patients and healthy postmenopausal women,” Orthopaedic Surgery, vol. 11, no. 6, pp. 1187–1200, 2019.
[26] T. Yu, X. You, H. Zhou et al., “p53 plays a central role in the development of osteoporosis,” Aging, vol. 12, no. 11, pp. 10473–10487, 2020.
[27] T. Yu, Q. Wu, X. You et al., “Tomatidine alleviates osteoporosis by downregulation of p 53,” Medical Science Monitor, vol. 26, article e923996, 2020.
I. Roato, G. Brunetti, E. Gorassini et al., "IL-7 up-regulates TNF-alpha-dependent osteoclastogenesis in patients affected by solid tumor," *PLoS One*, vol. 1, no. 1, article e124, 2006.

R. Zhao, "Immune regulation of osteoclast function in postmenopausal osteoporosis: a critical interdisciplinary perspective," *International Journal of Medical Sciences*, vol. 9, no. 9, pp. 825–832, 2012.

P. M. Marozik, M. Tamulaitiene, E. Rudenka et al., "Association of vitamin D receptor gene variation with osteoporosis risk in Belarusian and Lithuanian postmenopausal women," *Frontiers in endocrinology*, vol. 9, p. 305, 2018.

Z. L. Zhang, E. Y. Liao, W. B. Xia et al., "Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension," *Osteoporosis International*, vol. 26, no. 9, pp. 2365–2374, 2015.

M. De Martinis, M. M. Sirufo, M. Suppa, and L. Ginaldi, "IL-33/IL-31 Axis in Osteoporosis," *International Journal of Molecular Sciences*, vol. 21, no. 4, 2020.

W. Wang, J. Bai, W. Zhang et al., "Protective effects of punicalagin on osteoporosis by inhibiting osteoclastogenesis and inflammation via the NF-κB and MAPK pathways," *Frontiers in Pharmacology*, vol. 11, p. 696, 2020.

G. F. Qian, L. S. Yuan, M. Chen et al., "PPWD1 is associated with the occurrence of postmenopausal osteoporosis as determined by weighted gene coexpression network analysis," *Molecular Medicine Reports*, vol. 20, no. 4, pp. 3202–3214, 2019.

T. D. Prickett, B. Zerlanko, J. J. Gartner et al., "Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin," *The Journal of Investigative Dermatology*, vol. 134, no. 2, pp. 452–460, 2014.

L. Liu, M. Zhao, Z. G. Xie et al., "Twelve new genomic loci associated with bone mineral density," *Frontiers in Endocrinology*, vol. 11, p. 243, 2020.

P. I. Lin, Y. T. Tai, W. P. Chan, Y. L. Lin, M. H. Liao, and R. M. Chen, "Estrogen/ERα signaling axis participates in osteoblast maturation via upregulating chromosomal and mitochondrial complex gene expressions," *Oncotarget*, vol. 9, no. 1, pp. 1169–1186, 2018.

J. Huang, J. Peng, G. Cao et al., "Hypoxia-induced MicroRNA-429 promotes differentiation of MC3T3-E1 osteoblastic cells by mediating ZFPM2 expression," *Cellular Physiology and Biochemistry*, vol. 39, no. 3, pp. 1177–1186, 2016.

J. R. Arron and Y. Choi, "Bone versus immune system," *Nature*, vol. 408, no. 6812, pp. 535-536, 2000.

E. M. Lewiecki, "Denosumab in postmenopausal osteoporosis: what the clinician needs to know," *Therapeutic Advances in Musculoskeletal Disease*, vol. 1, no. 1, pp. 13–26, 2009.

A. Cline-Smith, A. Axelbaum, E. Shashkova et al., "Ovariec-tomy activates chronic low-grade inflammation mediated by memory T cells, which promotes osteoporosis in mice," *Journal of Bone and Mineral Research*, vol. 35, no. 6, pp. 1174–1187, 2020.

K. Tilkeridis, G. Kiziridis, A. Ververidis et al., "Immunoporosis: a new role for invariant natural killer T (NKT) cells through overexpression of nuclear factor-κB ligand (RANKL)," *Medical Science Monitor*, vol. 25, pp. 2151–2158, 2019.